Several analysts have recently updated their ratings and price targets for Adamas Pharmaceuticals (NASDAQ: ADMS):

  • 8/11/2017 – Adamas Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
  • 8/9/2017 – Adamas Pharmaceuticals was given a new $45.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/9/2017 – Adamas Pharmaceuticals had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 8/5/2017 – Adamas Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/19/2017 – Adamas Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/11/2017 – Adamas Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) opened at 13.68 on Thursday. The firm has a 50-day moving average price of $17.02 and a 200-day moving average price of $16.82. Adamas Pharmaceuticals, Inc. has a 52-week low of $12.10 and a 52-week high of $19.50. The company’s market cap is $307.99 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the business earned ($0.78) EPS. The firm’s quarterly revenue was down 90.9% on a year-over-year basis. On average, analysts forecast that Adamas Pharmaceuticals, Inc. will post ($3.80) EPS for the current year.

In related news, major shareholder Great Point Partners Llc sold 350,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $17.05, for a total transaction of $5,967,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is owned by corporate insiders.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.